MediGene Receives Authorization for the Clinical Formulation Study of RhuDex
Dr. Frank Mathias, MediGene’s CEO, commented: “Preliminary formulations of RhuDex® permitted initial clinical trials of the drug candidate. For the long-term development and subsequent marketability of the product, however, we seek an improved formulation and dosage form of RhuDex® to facilitate a therapeutically ideal release of the active ingredient as well as patient-friendly dosing. We are delighted to be able to continue the clinical development of RhuDex® with an optimized product candidate.“
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.